30/07/2026
If the same fibrosis stage can coexist with different levels of disease activity, the starting question is not simply which test to run. It is what we need to measure.
One liver can raise three distinct questions:
How much fat is present?
How much structural damage has accumulated?
How much disease activity is present... and is it changing?
No single measurement answers all three.
MRI-PDFF quantifies liver fat. Fibrosis assessment characterizes accumulated structural burden and long-term risk. cT1 provides a quantitative measure of disease activity, adding complementary information about what is happening now in the liver as well as longitudinal tissue change.
These are not competing answers to the same question. They describe different dimensions of the same liver, and together can provide a more complete picture.
The question should determine the measurement.
Learn more about LiverMultiScan: https://perspectum.com/products/livermultiscan/